GRACE THERAPEUTICS INC
GRCENASDAQTrading Snapshot
- Day Range
- $2.10 – $2.13
- 52-Week Range
- $1.79 – $5.18
- Volume
- $4.28B
- Avg Volume
- $3.58B
- Shares Outstanding
- 16.3M
- Next Earnings
- Dec 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.24
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.0%
Why Investors Own GRCE
- ✓High-growth profile — revenue up +50.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GRACE THERAPEUTICS INC
GRCE
StockOtter · stockotter.spaceAbout GRACE THERAPEUTICS INC
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable form
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formu
Grace Therapeutics Announces $10 Million Private Placement
Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRI
Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened
Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report)'s share price fell 2.5% on Wednesday. The stock traded as low as $2.36 and last traded at $2.37. 103,999 shares traded hands during mid-day trading, a decline of